Moreover, in a retrospective study, Lee et al. performed tumor tissue genomic and transcriptomic profiling in a cohort of patients with HR+/HER2- MBC treated with palbociclib, ribociclib, or abemaciclib and hormone therapy in different lines. The gene discussed is ERBB2; the disease is neoplasm.